DRUG DISCOVERY ‘15 TELFORD INTERNATIONAL CONFERENCE CENTRE 2ND - 3RD SEPTEMBER 2015 www.elrig.org #ELRIGDD15 ONCOLOGY DRUG TARGETS Thursday September 3rd Room: Pattingham The translation of emerging knowledge of cancer biology into novel therapies remains a great challenge in drug discovery, and requires early collaboration between key stakeholders in academia and industry to ensure that the most relevant and actionable targets are taken forward. This session will focus on academia-industry collaboration models established in recent years, with sharing of examples of successful outcomes and lessons learned. A secondary focus will be on epigenetic mechanisms in cancer where pioneering work from organizations such as the Structural Genomics Consortium, has revealed a large number of potentially druggable proteins involved in the writing, reading and erasure of epigenetic marks. CHAIRS: Herbie Newell, Newcastle University. Hamish Ryder, Cancer Research Technology TIME 9:10 - 9:15 SPEAKER Session Chairs TITLE Introduction and Welcome 9:15 - 10:00 Keynote Speaker: Chas Bountra SGC, University of Oxford “We Must Work Together To Catalyse the Generation of More Novel and More Affordable Cancer Treatments” 10:00 - 10:30 Neil Thompson Astex Pharmaceuticals Optimising Oncology Drug Discovery via Partnerships Between Academia and Industry 10:30 - 11:00 COFFEE BREAK 11:00 - 11:30 Christian Dillon Cancer Research Technology Discovery Laboratory Building On an Atypical (PKC) Relationship – Innovative Drug Discovery Alliances in Oncology 11:30 - 12:00 POSTER TASTERS 12:00 - 12:30 SNAPSHOT PRESENTATIONS 12:30 - 14:00 LUNCH - EXHIBITION - POSTERS PLENARY KEYNOTE: ROOM - IRONBRIDGE The Development of New Therapeutics for respiratory 14:00 - 15:00 Professor Tracy Hussell inflammation Manchester Collaborative Centre for Inflammation Research 15:00 - 15:30 Christopher Schofield Oxford University Targeting Oxygenases for the Regulation of Protein Biosynthesis 15:30 - 16:00 Paul Fish UCL School of Pharmacy Chemical Probes for the Bromodomain of the BRPF Family 16:00 - 16:30 Ulf Bremberg Beactica Fragment-Based Lead Generation of Reversible Inhibitors for Lysine-Specific Demethylases 16:30 - 17:00 POSTER SESSION